Keyphrases
Irinotecan
100%
Response Evaluation
100%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
100%
Metastatic Colorectal Cancer (mCRC)
100%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Metabolic Response
100%
Cetuximab
100%
Computed Tomography
100%
Disease Rate
66%
Partial Response
50%
Metabolic Disease
50%
Response Rate
33%
Response Evaluation Criteria in Solid Tumors (RECIST)
33%
Morphological Response
33%
Progressive Disease
33%
KRAS mutation
33%
Stable Disease
33%
Metabolic
16%
Computed Tomography Examination
16%
Metabolic Therapy
16%
Non-responders
16%
Treatment Cycle
16%
Survival Status
16%
Treatment Response
16%
Tumor Response
16%
Hazard Ratio
16%
Response Distribution
16%
Overall Survival
16%
Phase II Trial
16%
Colorectal Cancer Patients
16%
Positron Emission Tomography
16%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Computer Assisted Tomography
100%
Irinotecan
100%
Deoxyglucose
100%
Metastatic Colorectal Cancer
100%
Cetuximab
100%
Metabolism
85%
Morphology
42%
Water-Electrolyte Imbalance
42%
Progressive Disease
28%
Solid Malignant Neoplasm
28%
Diseases
28%
positron emission tomographic scan
28%
Response Evaluation Criteria in Solid Tumors
28%
Colorectal Carcinoma
14%
Hazard Ratio
14%
Phase II Trials
14%
Overall Survival
14%
Treatment Response
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Deoxyglucose
100%
Metastatic Colorectal Cancer
100%
Irinotecan
100%
Solid Malignant Neoplasm
80%
Diseases
80%
Metabolic Disorder
60%
Phase II Trials
20%
Overall Survival
20%
Colorectal Carcinoma
20%
Immunology and Microbiology
Computer Assisted Tomography
100%
Irinotecan
100%
Positron Emission Tomography-Computed Tomography
100%
Metabolism
85%
Morphology
42%
positron emission tomographic scan
28%
Overall Survival
14%